VPC-18005

SKU: orb1301194

Description

VPC-18005 is a luciferase inhibitor that directly targets the ERG-ETS domain, blocking ERG's DNA binding and subsequent transcriptional activity. This small molecule is a valuable research tool for studying ERG-driven oncogenesis in prostate cancer and leukemia, applicable in both in vitro and in vivo experimental models.

Research Area

Cell Biology, Molecular Biology

Key Properties

• CAS Number: 2242480-48-2
• MW: 319.38
• Purity: 99.79% (May vary between batches)
• Formula: C₁₅H₁₇N₃O₃S
• SMILES: N(/N=C\C1=CC=C(C(C)C)C=C1)=C\2/SC(CC(O)=O)C(=O)N2
• Target: Others,DNA/RNA Synthesis
• Solubility: DMSO:60 mg/mL (187.86 mM)

Bioactivity

• In Vitro:
  VPC-18005 (1 and 10 µM) produced a 20–30% decrease in the dissemination of cancer cells in zebrafsh. VPC-18005 (5 µM) inhibits pETS-luc reporter activity with IC50s of 3 and 6 μM in PNT1B-ERG and VCaP cells, respectively. VPC-18005 antagonizes the metastatic potential of ERG-expressing prostate cells and suppresses ERG reporter activity without exhibiting overt cytotoxicity. VPC-18005 inhibits migration and invasion of ERG-overexpressing cells in vitro.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

cancer, inhibit, luciferase, Inhibitor, ETS, ERG, prostate, PNT1B, VPC 18005, VPC18005, VPC-18005

Compound Identifiers

PubChem CID

136192781